El Ibex salva la sesión y consolida los 14.000 puntos, apoyado en las renovables
Expansiónarrow_outwardLa Bolsa española sube el 0,3 % animada por Wall Street y a la espera del BCE Por EFE
Investing.com Españolarrow_outwardLos futuros del Ibex 35 siguen en rojo, pero no se alejan de los 14.000 puntos
Estrategias de Inversiónarrow_outwardIs Grifols S.A. Depositary Receipt a good long term investment - Explosive earnings growth - jammulinksnews.com
Jammulinksnews.comarrow_outwardWomen's EURO 2025 top scorer: Esther González - UEFA.com
UEFA.comarrow_outwardGrifols S.A. Depositary Receipt Stock Analysis and Forecast - Skyrocketing profit margins - Autocar Professional
Autocar Professionalarrow_outwardGrifols: Reassuring Evidence, Still On The Sidelines - Seeking Alpha
Seeking Alphaarrow_outwardGrifols to build new €160-million fractionation plant in Spain to double European production capacity - The Corner .eu
The Corner .euarrow_outwardGrifols will invest €160 million in a new plant in Lliçà de Vall. - Diari ARA
Diari ARAarrow_outwardEquipment failure at Winnipeg clinic caused blood plasma donor's kidney injury, lawsuit alleges - CBC
CBCarrow_outwardGrifols shares rise 3.28% premarket after announcing a new manufacturing site in Spain to double plasma fractionation capacity. - AInvest
AInvestarrow_outwardGrifols’s Family Blood Is Thicker Than Water - Bloomberg
Bloombergarrow_outwardGrifols Case Shows It Paid Family-Linked Entity More for Plasma - Mint
Mintarrow_outwardOsborne Clarke advises Grifols on delisting offer and delisting from stock exchange of Biotest - Osborne Clarke
Osborne Clarkearrow_outwardAshurst advises Biotest on the public delisting offer by GRIFOLS and its delisting from the Frankfurt Stock Exchange - Ashurst
Ashurstarrow_outwardXL-protein grants worldwide license to Grifols - European Pharmaceutical Manufacturer
European Pharmaceutical Manufacturerarrow_outwardGrifols Completes Acquisition of Biotest Shares Following Delisting - TipRanks
TipRanksarrow_outwardGlobal Moves: Iberdrola, ACS, Grifols, And Aena's Strategic Expansions - Finimize
Finimizearrow_outwardXL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology - GlobeNewswire
GlobeNewswirearrow_outwardXL-protein and Grifols ink global biopharma licensing deal - The Pharma Letter
The Pharma Letterarrow_outwardGrifols Sues Gotham Over Defamation Free Speech and Stock Fallout - Lawyer Monthly
Lawyer Monthlyarrow_outwardFDA clears Grifols’ application for dry eye disease treatment - Clinical Trials Arena
Clinical Trials Arenaarrow_outwardFDA clears Grifols' Investigational New Drug application for immunoglobulin drops for the treatment of DED - Ophthalmology Times
Ophthalmology Timesarrow_outwardIND Application Cleared for Phase II Trial of Grifols’ Dry Eye Disease Drops - PharmTech
PharmTecharrow_outwardGrifols reports Q1 adjusted EBITDA of EUR 400M, up 14.2% from last year - Yahoo Finance
Yahoo Financearrow_outwardGrifols says on course to meet 2025 outlook as net profit triples - Yahoo.co
Yahoo.coarrow_outwardIBL partners with Grifols to develop biomarker panels for speciality diagnostics - Medical Device Network
Medical Device Networkarrow_outwardIBL International collaborates with Grifols on advanced biomarker panels - Business Wire
Business Wirearrow_outwardGrifols and Inpeco joining forces to deliver transfusion medicine ‘lab of the future’ - SelectScience
SelectSciencearrow_outwardGrifols - drugdiscoverytrends.com
Drugdiscoverytrends.comarrow_outwardSpanish pharma company Grifols' shares up on Brookfield talk - Reuters
Reutersarrow_outwardGrifols shares surge on reports of fresh Brookfield bid - Sharecast.com
Sharecast.comarrow_outwardGrifols Chair Symposium: Translating Science into the Clinic - Hospital Clínic Barcelona
Hospital Clínic Barcelonaarrow_outwardThe importance of time: Grifols seeks biomarkers for early diagnosis of disease - pharmaphorum
Pharmaphorumarrow_outwardGrifols IVIG Shows Promise for Post-Polio Syndrome - Contract Pharma
Contract Pharmaarrow_outwardLandmark study aims to detect Parkinson’s before symptoms - Drug Target Review
Drug Target Reviewarrow_outwardGrifols collaborates with startup FcR Therapeutics to develop autoimmune therapies - PharmaTimes
PharmaTimesarrow_outwardSpain accused of 'scaring off and intimidating' short-sellers in Grifols case - IFR Asia
IFR Asiaarrow_outwardGrifols garners $21M grant from Michael J. Fox Foundation to hunt for early Parkinson's disease biomarkers - Fierce Biotech
Fierce Biotecharrow_outwardSpain: Grifols ends acquisition discussions with Brookfield - Investors in Healthcare
Investors in Healthcarearrow_outwardGrifols shares sink after Brookfield walks away from €6.45bn offer - Financial Times
Financial Timesarrow_outwardGrifols rejects Brookfield’s ‘undervalued’ $6.8bn bid - Private Equity Wire
Private Equity Wirearrow_outwardPlasma specialist Grifols shrugs off private equity firm Brookfield's potential €6.5B takeover offer - Fierce Pharma
Fierce Pharmaarrow_outwardCourt accepts complaint against Gotham for spreading 'biased and misleading' information about Grifols - Catalan News
Catalan Newsarrow_outwardBrookfield weighing €7B takeout of Spain's troubled Grifols: report - FirstWord Pharma
FirstWord Pharmaarrow_outward
Grifols close
- 2025-07-23 04:00 event
- 45 sourceslanguage
- 200+ ads_click
- 3 weeks ago schedule